Riptylimab

Preclinical

Riptylimab is one of 2 therapeutic programs targeting Neuromyelitis Optica Spectrum Disease (NMOSD). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Neuromyelitis Optica Spectrum Disease (NMOSD)Not yet recruiting

Neuromyelitis Optica Spectrum Disease (NMOSD)Preclinical

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Neuromyelitis Optica Spectrum Disease (NMOSD)

#DrugCompanyPhaseTrials

Ripertamab

ZZhongming Qiu

Preclinical

1 2

Riptylimab

ZZhongming Qiu

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

PreclinicalNot yet recruiting

Neuromyelitis Optica Spectrum Disease (NMOSD)

NCT07685678

Clinical

Trials by Indication[1]

Neuromyelitis Optica Spectrum Disease (NMOSD)1 trial

Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders

Not yet recruiting·ZZhongming Qiu·Preclinical·NCT07685678·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Riptylimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Riptylimab. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Zhongming Qiu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: ZZhongming Qiu

Riptylimab

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Neuromyelitis Optica Spectrum Disease (NMOSD)1 trial

References

Drug Info

Quick Facts

Related News